2023-11-01 2024-10-31 false No description of principal activity Acting Office - Tax and Accounts 1.0 11640822 bus:FullAccounts 2023-11-01 2024-10-31 11640822 bus:Micro-entities 2023-11-01 2024-10-31 11640822 bus:AuditExempt-NoAccountantsReport 2023-11-01 2024-10-31 11640822 bus:SmallCompaniesRegimeForAccounts 2023-11-01 2024-10-31 11640822 bus:PrivateLimitedCompanyLtd 2023-11-01 2024-10-31 11640822 2023-11-01 2024-10-31 11640822 2024-10-31 11640822 bus:RegisteredOffice 2023-11-01 2024-10-31 11640822 core:WithinOneYear 2024-10-31 11640822 core:AfterOneYear 2024-10-31 11640822 2022-11-01 11640822 bus:Director1 2023-11-01 2024-10-31 11640822 bus:Director1 2024-10-31 11640822 bus:Director1 2022-11-01 2023-10-31 11640822 bus:CompanySecretary1 2023-11-01 2024-10-31 11640822 bus:LeadAgentIfApplicable 2023-11-01 2024-10-31 11640822 2022-11-01 2023-10-31 11640822 2023-10-31 11640822 core:WithinOneYear 2023-10-31 11640822 core:AfterOneYear 2023-10-31 11640822 bus:EntityAccountantsOrAuditors 2022-11-01 2023-10-31 11640822 core:FurnitureFittings 2023-11-01 2024-10-31 11640822 core:FurnitureFittings 2024-10-31 11640822 core:FurnitureFittings 2023-10-31 11640822 core:ComputerEquipment 2023-11-01 2024-10-31 11640822 core:ComputerEquipment 2024-10-31 11640822 core:ComputerEquipment 2023-10-31 11640822 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2024-10-31 11640822 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2023-10-31 11640822 core:Goodwill 2023-11-01 2024-10-31 11640822 core:Goodwill 2024-10-31 11640822 core:Goodwill 2023-10-31 11640822 core:CostValuation core:Non-currentFinancialInstruments 2024-10-31 11640822 core:CostValuation core:Non-currentFinancialInstruments 2023-10-31 11640822 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-10-31 11640822 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2024-10-31 11640822 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2024-10-31 11640822 core:Non-currentFinancialInstruments 2024-10-31 11640822 core:Non-currentFinancialInstruments 2023-10-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 11640822
England and Wales

 

 

 


Report of the Director and Unaudited Financial Statements

for the year ended 31 October 2024

for

BIOPOISE CONSULTING LTD

 
 
 
£
2024
£
   
£
2023
£
Fixed assets 2,195  3,066 
Current assets 371,162  383,345 
Creditors: amount falling due within one year (8,367) (10,440)
Net current assets/(liabilities) 362,795  372,905 
Total assets less current liabilities 364,990  375,971 
Accrued liabilities (317)
Net assets/(liabilities) 364,990  375,654 
 
Capital and reserves 364,990  375,654 
 
  1. For the year ended 31 October 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
  2. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006.
  3. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

Signed on behalf of the board of directors:


----------------------------------
Gbenga Olasehinde
Director

Date approved: 15 May 2025
1
Statutory Information
BIOPOISE CONSULTING LTD is a private limited company, limited by shares, domiciled in England and Wales, registration number 11640822, registered office 44 Crosby Road, Dagenham, RM10 9AS, United Kingdom.

The presentation currency is £ sterling.
1.

Accounting Policies

Basis of accounting
The financial statements are prepared under the historical cost convention and in accordance with the FRS 105 Financial Reporting Standard for Micro Entities (effective January 2016).
2.

Average number of employees

Average number of employees during the year was 1 (2023: 1).
3.

Director Advances Credits Note

As at the 31 October 2024, the director owed £1,645.55 to Biopoise Consulting Ltd (£0 at 31 October 2023).
2